



AMENDMENT UNDER 37 CFR 1.116
EXPEDITED PROCEDURE -
EXAMINING GROUP 1624

PATENT
Attorney Docket No.: 021390-002040US
Client Ref. No.: MPI00-596P3RNCP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Scarborough et al.

Application No.: 09/920,325

Filed: August 2, 2001

For: PLATELET ADP RECEPTOR
INHIBITORS

Customer No.: 20350

Confirmation No.: 5032

Examiner: Bruck Kifle

Technology Center/Art Unit: 1624

AMENDMENT UNDER 37 CFR 1.116
EXPEDITED PROCEDURE EXAMINING
GROUP 1624

RECEIVED
NOV 20 2003
TECH CENTER 1600/2900

Mail Stop: AF
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the *final* Office Action mailed July 14, 2003, please enter the following amendments and remarks:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 33 of this paper.